Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för tilmacoxib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

10 träffar

Bibliografisk träff 2010-04-13

Enhancement of the sensitivity of renal cell carcinoma cells to fas-mediated cytotoxicity and apoptosis by the selective cyclooxygenase-2 inhibitor JTE-522.

Sato N, Mizutani Y, Li YN, Fujiwara J, Ishida H, Toiyama D, Abe K, Hayashi I, Nakanishi H, Kawauchi A, Miki T.

Urol Int · journal article · DOI 10.1159/000288243

Bibliografisk träff 2010-01-01

Preventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on DEN-induced hepatocarcinogenesis in rats.

Nagahara T, Okano J, Fujise Y, Abe R, Murawaki Y.

Biomed Pharmacother · journal article · DOI 10.1016/j.biopha.2009.09.023

Bibliografisk träff 2007-11-01

Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cells.

Nagahara T, Okano J, Murawaki Y.

Oncol Rep · journal article · DOI 10.3892/or.18.5.1281

Bibliografisk träff 2006-04-01

Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial.

Iwama T, Akasu T, Utsunomiya J, Muto T.

Int J Clin Oncol · multicenter study; randomized controlled trial; journal article · DOI 10.1007/s10147-005-0548-z

Bibliografisk träff 2003-08-01

JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1.

Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K, Sugita Y, Chang-De J, Kobayashi S, Damdinsuren B, Dono K, Umeshita K, Sekimoto M, Sakon M, Matsuura N, Monden M.

Gastroenterology · research support, non-u.s. gov't; journal article · DOI 10.1016/s0016-5085(03)00904-1

Bibliografisk träff 2002-11-01

Pharmacokinetics and safety of JTE-522, a novel selective cyclooxygenase-2 inhibitor, in healthy male volunteers.

Ikeda Y, Umemura K, Kondo K, Nakashima M, Kobayashi T, Takahashi M.

Br J Clin Pharmacol · research-article; journal article · DOI 10.1046/j.1365-2125.2002.01676.x

Bibliografisk träff 2000-11-01

An experimental model of tumor dormancy therapy for advanced head and neck carcinoma.

Nishimura G, Yanoma S, Satake K, Ikeda Y, Taguchi T, Nakamura Y, Hirose F, Tsukuda M.

Jpn J Cancer Res · comparative study; brief-report; journal article · DOI 10.1111/j.1349-7006.2000.tb00905.x

Bibliografisk träff 2000-03-01

JTE-522 selectively inhibits cyclooxygenase-2-derived prostaglandin production in inflammatory tissues.

Wakitani K, Tazaki H, Matsushita M, Iwamura H.

Inflamm Res · journal article · DOI 10.1007/s000110050568

Bibliografisk träff 1998-11-01

Profile of JTE-522 as a human cyclooxygenase-2 inhibitor.

Wakitani K, Nanayama T, Masaki M, Matsushita M.

Jpn J Pharmacol · journal article · DOI 10.1254/jjp.78.365

Bibliografisk träff 1997-11-01

Pharmacological profile of JTE-522, a novel prostaglandin H synthase-2 inhibitor, in rats.

Matsushita M, Masaki M, Yagi Y, Tanaka T, Wakitani K.

Inflamm Res · journal article · DOI 10.1007/s000110050225